Donghyun Hong1, Georgios Batsios1, Pavithra Viswanath1, Anne Marie Gillespie1, Russell O Pieper2,3, Joseph Costello2, and Sabrina M Ronen 1,3
1Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, United States, 2Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, United States, 3Brain Tumor Research Center, University of California San Francisco, San Francisco, CA, United States
1Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, United States, 2Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, United States, 3Brain Tumor Research Center, University of California San Francisco, San Francisco, CA, United States
Here we treated mutant IDH1-expressing cells with the emerging inhibitor BAY-1436032 and identified translatable MRS based metabolic biomarkers of mutant IDH1 inhibition using 1H and hyperpolarized 13C spectroscopy.
Figure 1. Representative 1H MRS spectra of control and treated NHAIDH1mut cells.
Figure 3. (A) shows fluxed from the hyperpolarized [1-13C]α-ketoglutarate to glutamate between control (blue) and the BAY-1436032 treated (orange) cells. A significant increase in glutamate was observed in the BAY-1436032 cells (B)
